Shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) traded up 2.7% on Thursday . The company traded as high as $49.80 and last traded at $49.77, with a volume of 228,912 shares traded. The stock had previously closed at $48.46.

A number of analysts recently weighed in on the stock. Jefferies Group reiterated a “buy” rating on shares of Neurocrine Biosciences in a research note on Sunday, May 8th. Robert W. Baird restated a “buy” rating on shares of Neurocrine Biosciences in a research report on Sunday, May 8th. Leerink Swann restated an “outperform” rating and set a $63.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, June 1st. Piper Jaffray Cos. restated an “overweight” rating and set a $96.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, May 16th. Finally, Cowen and Company restated a “buy” rating and set a $65.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $63.90.

The company has a 50 day moving average of $49.20 and a 200 day moving average of $44.69. The firm’s market cap is $4.29 billion.

In related news, Director Corinne H. Nevinny sold 5,000 shares of the company’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $48.54, for a total value of $242,700.00. Following the completion of the transaction, the director now directly owns 25,555 shares in the company, valued at $1,240,439.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Malcolm Lloyd-Smith sold 9,000 shares of the company’s stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $50.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now owns 9,000 shares of the company’s stock, valued at $450,000. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Neurocrine Biosciences stock. I.G. Investment Management LTD. acquired a new stake in Neurocrine Biosciences Inc. (NASDAQ:NBIX) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 45,000 shares of the company’s stock, valued at approximately $2,546,000. I.G. Investment Management LTD. owned approximately 0.05% of Neurocrine Biosciences at the end of the most recent quarter.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.